Insider · CIK 0001451805

Amello Jason

Reports to the SEC for 6 companies · WALTHAM, MA

sec.gov

Transactions

Companies

Filings

CIK

0001451805

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-01-20	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+350K sh	—	—	350,000
2025-01-03	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+270K sh	—	—	270,000
2024-02-01	TCRXTScan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+750K sh	—	—	750,000
2023-11-28	CADLCandel Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−20.2K sh	$0.90	−$18.1K	202,009
2023-11-26	CADLCandel Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+126K sh	—	—	222,162
2023-04-28	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+90K sh	—	—	90,000
2023-03-14	Acer Therapeutics Inc.Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-12-09	CADLCandel Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,468 sh	$1.93	+$4,763.24	5,568
2022-12-08	CADLCandel Therapeutics, Inc.P Purchase	Chief Financial Officer	PPurchase	+3,100 sh	$1.69	+$5,239	3,100
2022-11-28	CADLCandel Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+90.9K sh	—	—	90,877
2022-09-21	CADLCandel Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+230K sh	—	—	230,000
2022-01-14	Acer Therapeutics Inc.Stock Option (right to buy)A Award	Director	AAward	+18.5K sh	—	—	18,500
2021-01-15	Acer Therapeutics Inc.Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-02-28	AKBAAkebia Therapeutics, Inc. · Stock Option (Right to buy)A Award	SVP, CFO & Treasurer	AAward	+45K sh	—	—	45,000
2020-02-28	AKBAAkebia Therapeutics, Inc.S Sale	SVP, CFO & Treasurer	SSale	−6,976 sh	$8.70	−$60.7K	144,642
2020-02-28	AKBAAkebia Therapeutics, Inc.A Award	SVP, CFO & Treasurer	AAward	+30K sh	—	—	151,618
2020-01-02	Acer Therapeutics Inc.Stock Option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2019-04-11	AKBAAkebia Therapeutics, Inc.D Disposition to Issuer	SVP, CFO & Treasurer	DDisposition to Issuer	−13.1K sh	$7.70	−$101K	118,618
2019-02-28	AKBAAkebia Therapeutics, Inc. · Employee Stock Option (Right to buy)A Award	SVP, CFO & Treasurer	AAward	+100K sh	—	—	100,000
2019-02-28	AKBAAkebia Therapeutics, Inc.A Award	SVP, CFO & Treasurer	AAward	+65K sh	—	—	131,766
2019-02-01	Acer Therapeutics Inc.Employee Stock Option (right to buy)A Award	Director	AAward	+6,000 sh	—	—	6,000
2018-12-12	AKBAAkebia Therapeutics, Inc.F Tax Payment	SVP, CFO & Treasurer	FTax Payment	−22.2K sh	$8.94	−$199K	66,501
2018-02-28	AKBAAkebia Therapeutics, Inc.A Award	SVP, CFO & Treasurer	AAward	+19.5K sh	—	—	87,236
2018-02-28	AKBAAkebia Therapeutics, Inc. · Employee Stock Option (Right to buy)A Award	SVP, CFO & Treasurer	AAward	+27.7K sh	—	—	27,700
2017-10-04	Acer Therapeutics Inc.Stock Option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2017-02-21	AKBAAkebia Therapeutics, Inc. · Stock Option (Right to buy)A Award	SVP, CFO & Treasurer	AAward	+47.5K sh	$10.14	+$482K	47,500
2017-02-21	AKBAAkebia Therapeutics, Inc.A Award	SVP, CFO & Treasurer	AAward	+30K sh	—	—	65,637
2016-02-22	AKBAAkebia Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, CFO & Treasurer	AAward	+39.7K sh	—	—	39,650
2016-02-22	AKBAAkebia Therapeutics, Inc.A Award	SVP, CFO & Treasurer	AAward	+26K sh	—	—	33,330
2015-03-06	AKBAAkebia Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, CFO & Treasurer	AAward	+45K sh	—	—	45,000
2014-11-26	AKBAAkebia Therapeutics, Inc.P Purchase	SVP, CFO & Treasurer	PPurchase	+1,000 sh	$13.22	+$13.2K	5,000
2014-05-14	AKBAAkebia Therapeutics, Inc. · Stock Option (Right to Buy)A Award	SVP, CFO & Treasurer	AAward	+21.7K sh	—	—	21,667
2014-03-25	AKBAAkebia Therapeutics, Inc.P Purchase	SVP, CFO & Treasurer	PPurchase	+4,000 sh	$17.00	+$68K	4,000
2013-05-08	TCRTAlaunos Therapeutics, Inc.F Tax Payment	Executive Vice President & CFO	FTax Payment	−2,623 sh	$1.65	−$4,327.95	22,377
2012-12-31	TCRTAlaunos Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Executive Vice President & CFO	AAward	+150K sh	—	—	150,000
2012-06-20	TCRTAlaunos Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Executive Vice President & CFO	AAward	+200K sh	—	—	200,000
2012-05-08	TCRTAlaunos Therapeutics, Inc.A Award	Executive Vice President & CFO	AAward	+25K sh	—	—	25,000
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−4,340 sh	$51.52	−$224K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−5,455 sh	$58.66	−$320K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−5,220 sh	$68.48	−$357K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−4,725 sh	$62.16	−$294K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−8,640 sh	$58.50	−$505K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−9,300 sh	$62.98	−$586K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−11.6K sh	$43.90	−$509K	0
2011-04-04	GENZYME CORPStock Option (right to buy)D Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−4,000 sh	$48.38	−$194K	0
2011-04-04	GENZYME CORPD Disposition to Issuer	CorpContrllr,ChiefAccntOfficer	DDisposition to Issuer	−5,005 sh	$74.00	−$370K	0
2011-04-04	GENZYME CORPRestricted Stock UnitsM Exercise/Conversion	CorpContrllr,ChiefAccntOfficer	MExercise/Conversion	−1,818 sh	—	—	0
2011-04-04	GENZYME CORPRestricted Stock UnitsM Exercise/Conversion	CorpContrllr,ChiefAccntOfficer	MExercise/Conversion	−1,740 sh	—	—	0
2011-04-04	GENZYME CORPRestricted Stock UnitsM Exercise/Conversion	CorpContrllr,ChiefAccntOfficer	MExercise/Conversion	−1,447 sh	—	—	0
2011-04-04	GENZYME CORPU Disposition from Tender	CorpContrllr,ChiefAccntOfficer	UDisposition from Tender	−2,084 sh	$74.00	−$154K	5,005

Recent filings

Accepted (ET)
Jan 224
Amello Jason0001193125-26-019729
SEC(opens sec.gov)
Feb 114
Amello Jason0000950170-25-018120
SEC(opens sec.gov)
Feb 24
Amello Jason0000950170-24-010522
SEC(opens sec.gov)
Nov 304
Amello Jason0001209191-23-056981
SEC(opens sec.gov)
Nov 284
Amello Jason0001209191-23-056802
SEC(opens sec.gov)
May 24
Amello Jason0001209191-23-026542
SEC(opens sec.gov)
Mar 164
Amello Jason0001209191-23-019289
SEC(opens sec.gov)
Dec 124
Amello Jason0001209191-22-060691
SEC(opens sec.gov)
Nov 304
Amello Jason0000899243-22-037232
SEC(opens sec.gov)
Sep 234
Amello Jason0001209191-22-051131
SEC(opens sec.gov)
Jan 194
Amello Jason0001209191-22-003701
SEC(opens sec.gov)
Jan 204
Amello Jason0001209191-21-004256
SEC(opens sec.gov)
Mar 24
Amello Jason0001562180-20-001935
SEC(opens sec.gov)
Jan 34
Amello Jason0001209191-20-000814
SEC(opens sec.gov)
Apr 124
Amello Jason0000899243-19-010587
SEC(opens sec.gov)
Mar 54
Amello Jason0001562180-19-001675
SEC(opens sec.gov)

Companies

Address

C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET

WALTHAM, MA, 02451